Trial Profile

Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florzolotau (Primary)
Indications Progressive supranuclear palsy
Focus Diagnostic use
Sponsors Invicro

Most Recent Events

20 Feb 2025 Status changed from recruiting to completed.
06 Oct 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
06 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com